BSX

Boston Scientific CorporationHealthcare / Medical DevicesINTACT

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Share Price
$42.98
52W: $42.2 - $105.65
DCF Fair Value
$33.22
-29.4% Premium
P/E (TTM)
17.4x
ROIC
17.2%
Operating Margin
22.9%
FCF Yield
3.9%
Debt / Equity
0.5x
Piotroski Score
8/9
Altman Z-Score
3.56
Market Cap
$62.3B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($33.22)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)
()
Period Range
$ - $
DCF Fair Value
$33.22
MOS Buy Target (-25%)
$24.92
Valuation Overlays:

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price
$42.98
DCF Fair Value
$33.27
-29.2% Premium
$2,451M
$100M$2,451M (Reported)$50,000M
11.5%
-5%10% (Target)35%
4.5%
0%5%20%
9.0%
6%9% (Standard)15% (High Risk)
2.5%
1% (GDP Floor)2.5% (Inflation)4.0%
$12,100M
-$100B CashBalance Sheet+$150B Debt
10-Yr PV of Cash Flows
$25.2B
PV of Terminal Value
$35.1B
Implied Enterprise Value
$60.3B
Implied Equity Value
$48.2B
YearYr 1Yr 2Yr 3Yr 4Yr 5Yr 6Yr 7Yr 8Yr 9Yr 10
Projected FCF ($M)$2,733$3,047$3,398$3,788$4,224$4,414$4,613$4,820$5,037$5,264
Present Value (PV)$2,507$2,565$2,624$2,684$2,745$2,632$2,523$2,419$2,319$2,223

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-38.9% Premium
$30.94

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $2.47BVPS: $17.23
Revised Graham Formula+26.1% MoS
$58.19

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Buffett Owner Earnings3.7% Yield
$1.61 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $2.3BYield: 3.7%

Reverse DCF: Market Growth Expectation

FAIR BARRIER
8.8% CAGR (Next 10 Yrs)

At the current price of $42.98, the market is assuming the business will compound Free Cash Flow at 8.8% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict
ℹ Fair expectations: Requires steady execution.
Autonomous Thesis Underwriting

Surveil BSX with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Boston Scientific Corporation. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 22.9% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Frequently Asked Questions: Boston Scientific Corporation (BSX) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Boston Scientific Corporation.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Boston Scientific Corporation has an estimated DCF intrinsic fair value of $33.22 per share compared to its current market price of $42.98. This represents an estimated 29.4% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $30.95.

Related Healthcare Value Stocks & Sector Peers

Compare Boston Scientific Corporation with audited intrinsic valuation models across the Healthcare sector.

View All S&P 500 Stocks